MOROSI, MANUELA
MOROSI, MANUELA
Universita' degli Studi di MILANO
International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia
2019 S. Aliberti, G.S. Cook, B.L. Babu, L.F. Reyes, A. H Rodriguez, F. Sanz, N.J. Soni, A. Anzueto, P. Faverio, R.F. Sadud, I. Muhammad, C. Prat, E. Vendrell, J. Neves, E. Kaimakamis, A. Feneley, R. Swarnakar, F. Franzetti, M. Carugati, M. Morosi, E. Monge, M.I. Restrepo
Lung ultrasound in the management of pneumocystis pneumonia : a case series
2019 S. Limonta, E. Monge, M. Montuori, M. Morosi, M. Galli, F. Franzetti
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
2014 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, B. Vergani, M. Morosi, E. Colella, M. Galli, S. Rusconi
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
2013 S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D'Annunzio, A. Di Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, G. D'Ettorre, D. Francisci, G. Parruti, A. Soria, A.R. Buonomini, C. Tommasi, S. Mosti, F. Bai, S. Di Nardo Stuppino, M. Morosi, M. Montano, P. Tau, E. Merlini, G. Marchetti
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients
2012 A. Giacomelli, M. Franzetti, B. Vergani, L. Oreni, M. Morosi, V. Di Cristo, E. Colella, O. Viganò, M. Galli, S. Rusconi